- About the VMC
- Pet Owners
- Farm Animal Owners
- Horse Owners
- Clinical Trials Office
The Ohio State University Clinical Trials Office at the Veterinary Medical Center is currently recruiting dogs diagnosed with malignant mammary carcinoma, melanoma, oral squamous cell carcinoma, or soft tissue sarcoma to participate in a clinical trial to explore and define the biological changes in these tumors and normal tissues following exposure to the chemotherapeutic drug iniparib. This is a Comparative Oncology Trials Consortium (COTC) clinical trial coordinated through the Comparative Oncology Program at the National Cancer Institute (NCI). COTC018: Evaluation of iniparib in tumor bearing dogs to define its pharmacokinetic profile and biological activity is designed to answer questions about iniparib and its metabolite pharmacokinetics and biological activity in tumors, normal tissues and surrogates. Mining for novel biomarkers or signatures of iniparib mechanism is the study's main objective. Exposure-pharmacodynamic relationships will also be defined. Data generated through this effort will inform the use and development of iniparib for clinical studies in human cancer patients.
To qualify for enrollment in this study, dogs must have:
The following are required for enrollment and can be performed at the OSU-VMC < 3 days before drug administration:
The following must be performed on Day 1 prior to drug administration:
Owner compensation will consist of the sponsor covering all study associated costs once enrolled in the study as well as provide clients with a $1,000 OSU-CVM account credit for any further veterinary care for their pet.